Navigation Links
iCardiac Reports Significant Revenue Growth and Profitability
Date:2/23/2009

iCardiac Continues to Successfully Leverage Differentiated Service and Product Offering

Rochester, New York (PRWEB) February 23, 2009 -- iCardiac Technologies, Inc., a leading innovator in advanced cardiac safety biomakers and automated QT analysis, today announced that the company has experienced significant revenue growth as its quarter over quarter revenues have grown in excess of 100%. Pharmaceutical and biotechnology companies continue to select iCardiac as a critical provider for their cardiac safety studies because of the company's scientific expertise, project management capabilities, as well as the industry's most advanced ECG analysis methodologies, which can both dramatically reduce the cost of cardiac safety studies in addition to reducing the likelihood of false-positives. Additionally, as iCardiac's revenues have continued to increase, the company achieved profitability in the last quarter of 2008.

iCardiac continues to advance the field of cardiac safety in Phase I, II, III as well as TQT studies through its end-to-end offering of cardiac safety analysis services. During 2009, iCardiac will aggressively continue to bring to market its Highly Automated QT(sm) and QT beat-to-beat offerings.

"To date our highly automated technology has been applied in over 10 clinical QT data analyses," said Sasha Latypova, Executive Vice President at iCardiac Technologies. "Pharmaceutical companies are gaining more accurate results and are substantially lowering the cost per Thorough QT study."

The drive to greater automation of the cardiac safety analysis process stems from general dissatisfaction in the industry regarding "gold standard" manual measurements that are both time-consuming and expensive. iCardiac's highly automated QT technology is different from "fully automated" approaches - which are based solely on computers - bec
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
2. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
3. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
4. New Study Reports Improved Patient Outcomes for Breast Cancer Patients
5. Zogenix Reports FDA Provides New PDUFA Date for Sumavel(TM) DosePro(TM)
6. Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results
7. Gentiva Reports Fourth Quarter and Fiscal 2008 Results
8. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
9. Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
10. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
11. YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
(Date:8/29/2014)... York (PRWEB) August 29, 2014 ... at $5.6 billion in 2019. It is expected ... 2013 to 2019, and was valued at $1.8 ... published by Transparency Market Research. , For more ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled ...
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... Research “Global Orthobiologics Market” the global orthobiologics market was valued ... reach a market worth USD 5,519.9million in 2019at a CAGR ... the population aged 50 years and above is afflicted by ... almost double by the year 2020. This has and will ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... SAN FRANCISCO, March 16 Medivation, Inc. (Nasdaq: ... and financial results for the fourth quarter and year ended December ... to an equally exciting 2009. We have made excellent progress across ... testing in all of our programs in 2009 -- Dimebon in ...
... 16 TauTaTis, Inc. announces that its lead compound ... process in Alzheimer,s Disease, has been recognized as the ... Disease gene LRRK2 reported to date. Mutations of ... are the most genetic frequent cause of Parkinson,s Disease.TauTaTis, ...
... Provider, Offers Traceability Down to the Unit Level to Secure ... ... Southborough, MA (PRWEB) March 16, 2009 -- PHARMORX ... technology services provider, today announced the availability of its new ...
Cached Biology Technology:Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 2Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 3Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 4Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 5Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 6Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 7Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update 8TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 3
(Date:8/29/2014)... Davis have made some surprising discoveries about the ... immunodeficiency virus (SIV), the team found that specialized ... early responders to viral invasion and are the ... called interleukin-1 beta (IL-1β). , Though aimed ... of the gut epithelium that provides a barrier ...
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and ... the UT Health Science Center at San Antonio, have ... the longest-lived rodent, the naked mole rat. , ... naked mole rats protects and alters the activity of ... proteins. , The factor also protects proteasome function in ...
(Date:8/29/2014)... about what genetic changes transform wild animals into domesticated ... is a University of Montana assistant professor, has made ... of the brain and the nervous system were particularly ... 28 in Science and gives answers to ... ., The domestication of animals and plants, a prerequisite ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... of the University of New Hampshire campus, David Berlinsky, assistant ... Inside, black sea bass circle slowly in the dim light. ... the College of Life Sciences and Agriculture, and home to ... many menus, but wild populations of the fish are in ...
... with hepatitis C virus (HCV) achieved significantly better ... Cyclosporine along with interferon-ribavirin combination therapy. Cyclosporine also ... , The results of this study appear ... the official journal of the American Association for ...
... infants born with HIV infection may be most effective ... according to a study published in the April 1 ... online. , Uncertainty over when to start antiretroviral treatment ... around balancing the benefits of preventing disease progression and ...
Cached Biology News:Uncovering sex-change secrets of black sea bass 2Cyclosporine inhibits hepatitis C virus in vitro 2New study shows benefit of early therapy in HIV-infected infants 2
Umbilical cord blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
... Coating Stabilizer has been developed ... or immobilized proteins on microwell plates/strips. ... and activity of the antibody or ... immunoassay components. Product is filtered ...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Biology Products: